Aligos Therapeutics, Inc. Common Stock

ALGSNASDAQ • USD
ThemeBiotech - Drug Development›Infectious Disease & Vaccines
4.91 USD
↘ 0.43 (8.05%)AT CLOSE (11:59 AM EDT)
5.07
↗ 0.16 (3.34%)
POST MARKET (AS OF 07:53 PM EDT)
Post Market
AS OF 07:53 PM EDT
5.07
↗ 0.16 (3.34%)
🔴Market: CLOSED
Open?$5.30
High?$5.34
Low?$4.80
Prev. Close?$5.34
Volume?128.4K
Avg. Volume?135.7K
VWAP?$4.98
Rel. Volume?0.95x
Bid / Ask
Bid?$4.80 × 100
Ask?$5.15 × 100
Spread?$0.35
Midpoint?$4.98
Valuation & Ratios
Market Cap?30.4M
Shares Out?5.4M
Float?4.6M
Float %?75.5%
P/E Ratio?N/A
P/B Ratio?0.96
EPS?-$14.60
Dividend?0.00%
Ex-Dividend?N/A

ALGS is currently priced at $4.91. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Themes
Biotech - Drug Development›Infectious Disease & VaccinesBiotech - Drug Development›Metabolic & Cardiometabolic
Employees
82
Market Cap
30.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.aligos.com
Listed
2020-10-16
Address
ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO, CA 94080
Phone: (800) 466-6059
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
35
Short Sent.?
35
Piotroski F-Score?2/9Weak
Altman Z-Score?-18.02Distress
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?11.51%High
Short Interest?535.2K
Days to Cover?3.5
Free Float4.6M
Avg Daily Volume155.2K
Settlement Date2026-05-15
Financial Health
Current Ratio?2.55Strong
Quick Ratio?2.55Strong
Cash Ratio?1.29Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
92/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.96CHEAP▾
P/S?
Peers
100
S&P
19
6.46FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.0CHEAP▾
EV/Sales?
Peers
100
S&P
97
0.10CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-284.1%WEAK▾
ROA?
S&P
3
-139.9%WEAK▾
Cash Flow & Enterprise
FCF?$-85185000
Enterprise Value?$486.2K
Fundamentals ratios updated end of day
MarketsMoversWatchlist